Table 2:
Unadjusted OUD Utilization and Outcomes by Clinician Telemedicine Group
| Clinician Telemedicine Use Group | ||||||
|---|---|---|---|---|---|---|
|
|
||||||
| Low | Medium | High | ||||
|
|
||||||
| Prea | Postb | Pre | Post | Pre | Post | |
| Clinicians (n) | 589 | 589 | 590 | 590 | 589 | 589 |
| Enrollees with OUD (n) | 2095 | 2102 | 2240 | 2068 | 1655 | 1641 |
| OUD Outpatient Visits | ||||||
| Total within 90 days post earliest visit (n) | 6,445 | 6,848 | 5,910 | 5,442 | 4,387 | 4,424 |
| Percent Telemedicine (%) | 0.2 | 2.4 | 0.1 | 23.4 | 1.2 | 62.3 |
| OUD Visit Volume c | ||||||
| Total | 3.1 | 3.3 | 2.6 | 2.6 | 2.6 | 2.7 |
| In-person | 3.1 | 3.2 | 2.6 | 2.1 | 2.5 | 1.1 |
| Telemedicine | 0.0 | 0.1 | 0.0 | 0.5 | 0.1 | 1.6 |
| MOUD Initiation and Supply (%) | ||||||
| ≥ 1 MOUD fill within 14 days | 15.3 | 15.2 | 13.8 | 14.6 | 14.7 | 13.7 |
| ≥ 1 MOUD fill within 90 days | 19.1 | 18.5 | 18.0 | 18.1 | 19.9 | 17.5 |
| ≥ 1 MOUD fill within 30–90 days among those with a fill within 14 days | 76.9 | 68.8 | 68.2 | 68.1 | 75.0 | 65.8 |
| MOUD Days-Supply | ||||||
| Among those ≥ 1 MOUD fill | 20.2 | 20.5 | 20.8 | 20.9 | 18.8 | 18.2 |
| OUD-Related Event within 90 Days Following Index Visit (%) | ||||||
| Overdose | 2.3 | 2.1 | 1.7 | 1.9 | 1.9 | 1.8 |
| Detoxification/Rehabilitation | 4.1 | 3.4 | 2.3 | 2.0 | 3.0 | 3.0 |
| Injection-Related Infection | 9.0 | 10.2 | 8.3 | 8.3 | 9.8 | 7.9 |
| Any OUD Related Event | 14.7 | 14.6 | 11.4 | 11.7 | 14.0 | 12.1 |
OUD: Opioid Use Disorder, MOUD: Medication for Opioid Use Disorder
a
Pre: March 14th, 2019 – March 13th, 2020
b
Post: March 14th, 2020 – March 13th, 2021
c
This refers to the total number of OUD visits an enrollee had in their 90 day episode.